Mammary Cell News 10.06 February 15, 2018 | |
| |
TOP STORYEradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1 In the study of immune receptor glycosylation, the authors showed that EGF induces programmed death ligand 1 (PD-L1) and receptor programmed cell death protein 1 interaction, requiring β-1,3-N-acetylglucosaminyl transferase expression in triple-negative breast cancer. [Cancer Cell] Abstract | Press Release | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Scientists demonstrated that estrogen (E2) differentially modulated nuclear factor-kappa B (NF-κB) activity according to treatment time. E2 initially had significant potential to suppress NF-κB activation; it completely blocked tumor necrosis factor alpha-induced activation of NF-κB. [Cell Death Discov] Full Article The single chain fragment variable (scFvs) inhibited cell growth of MDA-MB-231 cells significantly as compared to untreated cells. Growth inhibition of 58.6 and 53.1% were detected for scFv-I and scFv-II, respectively. [Breast Cancer Res Treat] Abstract Investigators demonstrated that triple-negative breast cancers cells are markedly sensitized to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis upon glutamine deprivation. [Cell Death Dis] Full Article Purified cholesterol oxidase was evaluated for its in vitro anticancer activities against five human cancer cell lines. The selectivity index values on rhabdomyosarcoma and breast cancer cell lines were 3.26 and 2.56; respectively. [Sci Rep] Full Article The activity of the Hsp90 inhibitor NVP-AUY922 was assessed in HER2 overexpressing breast cancer cell lines, including two cell line models of acquired trastuzumab-resistance. [Invest New Drugs] Abstract The authors investigated the role of MAPT-AS1 in the progression and paclitaxel resistance in breast cancer, and the regulation between MAPT-AS1 and its natural comparable sense transcripts MAPT. [Cell Biosci] Full Article Investigators characterized the kinetic parameters of inorganic phosphate (Pi) transport in the aggressive human breast cancer cell line, MDA-MB-231, and correlated Pi transport with cell migration and adhesion. [PLoS One] Full Article Scientists revealed that msh homeobox 1 (MSX1) was broadly expressed in normal human tissues, including breast tissues, but was frequently downregulated or silenced in breast cancer cell lines and primary tumors by promoter methylation. [Int J Mol Med] Abstract Citral Induced Apoptosis in MDA-MB-231 Spheroid Cells Citral was able to inhibit the growth of the MDA-MB-231 spheroids when compared to a monolayer culture of MDA-MB-231 cells at a lower IC50 value. To confirm the inhibition of spheroid self-renewal capacity, the primary spheroids were then cultured to additional passages in the absence of citral. [BMC Complement Altern Med] Full Article | |
| |
REVIEWSRole of Autophagy in Breast Cancer and Breast Cancer Stem Cells A summary of the mechanisms and roles of autophagy in breast cancer and cancer stem cells is presented. The potential value of such autophagy modulators in the development of novel breast cancer therapies is discussed. [Int J Oncol] Abstract Visit our reviews page to see a complete list of reviews in the mammary cell research field. | |
| |
INDUSTRY NEWSAthenex Meets Enrollment Target for Oraxol Phase III Clinical Trial in Metastatic Breast Cancer Athenex announced that the enrollment of patients is on target for the company to be able to conduct a second interim analysis in the Oraxol KX-ORAX-001 Phase III clinical trial in the third quarter of 2018. [Athenex] Press Release ERYTECH Selects Triple Negative Breast Cancer as Next Indication for Eryaspase ERYTECH Pharma announced the selection of triple negative breast cancer as the next target indication for broadening the scope of eryaspase development in solid tumors. [ERYTECH Pharma] Press Release MEI Pharma, Inc. announced that a planned interim review of data supports continuation of its multicenter, investigator sponsored, study evaluating ME-344, a novel mitochondrial inhibitor, in patients with HER2-negative breast cancer. [MEI Pharma, Inc.] Press Release | |
| |
POLICY NEWSTrump Science Budget Sows Confusion US president makes last-minute decision to abandon proposal for major cuts to National Institutes of Health, National Science Foundation and Department of Energy’s science office. [Nature News] Editorial Researchers Debate Whether Journals Should Publish Signed Peer Reviews Scientific journals should start routinely publishing the text of peer reviews for each paper they accept, said attendees at a meeting last week of scientists, academic publishers, and funding organizations. But there was little consensus on whether reviewers should have to publicly sign their critiques, which traditionally are accessible only to editors and authors. [ScienceInsider] Editorial
| |
EVENTSNEW Stem Cells in Disease Modeling and Drug Discovery (SCDMDD) 2018 Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Computational Biologist – Cancer Research (Cancer Research UK Manchester Institute) Postdoctoral Researcher – Breast Cancer (University of Oxford) Postdoctoral Scientist Opportunities – Biomedical Research (Cedars-Sinai) Postdoctoral Fellow – Cancer Research (Memorial Sloan Kettering Cancer Center) Research Fellow – Breast Immunology (Dana-Farber Cancer Institute) Postdoctoral Fellow – Cancer Biology (University of Arkansas for Medical Science) Postdoctoral Research Associate – Cancer Biology (King’s College London) Postdoctoral Researcher – Development of Novel Cancer Therapies (University of Oxford) Cancer Bioinformatician – Breast Cancer Research (The Institute of Cancer Research) Postdoctoral Associate – Breast Cancer Research (University of Miami) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Mammary Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|